Skin & Aesthetics

Skin & Aesthetics is the only V1 Juno protocol with primarily cosmetic rather than medical goals. The peptide evidence here is unusually phase-dependent: topical GHK-Cu has solid dermatology evidence for skin-appearance markers (collagen synthesis, fine lines, hair density) at cosmetic-grade concentrations. Systemic injectable peptides for skin (the Glow blend, GHK-Cu SubQ) are community practice with much thinner data. Melanotan for cosmetic tanning is editorially the most fraught peptide in the V1 catalog — the use case sits in tension with the well-established melanoma-risk story.

This protocol sequences honestly: start with what has dermatology evidence (topical), only layer the systemic options once you've validated the topical foundation, and treat the pigmentation layer as a separate considered decision with explicit risk framing. If you have a personal or family history of melanoma, multiple atypical nevi, or significant sun-exposure history, Phase 3 is not the right path for you. The Topical and Systemic phases stand alone for skin appearance.

If skin appearance is a clinical concern (acne, rosacea, psoriasis, eczema), see a dermatologist — this protocol is not the right tool for those.

Phases

1. Phase 1 — Topical foundation (GHK-Cu daily)

   ongoing daily

   GHK-Cu in cosmetic-grade topical serum or cream, applied daily after cleansing. Mechanism: copper tripeptide drives collagen synthesis + matrix-remodeling enzyme regulation. The dermatology trials are at this dose level and route — concentration typically 0.05-0.1% in commercial products. This is the most evidence-supported peptide intervention for skin appearance in the entire library.

   • GHK-Cu1 mg · daily · evening

     Cosmetic-grade topical serum at 0.05-0.1% concentration applied once daily, typically evening after cleansing. The dose_mcg field is approximate — topical formulations dose by concentration + application volume, not absolute mass. Adjust on /stack based on your product.

   What “working” looks like

   Subjective improvement in skin texture and tone over 4-8 weeks. Reduced fine lines around the eyes by 8-12 weeks. Slow improvement in scalp hair density (3-6 months if hair density is a goal). Cosmetic results are notoriously slow; consistency matters more than peak dose.

   Decision criteria

   If working at week 8: continue indefinitely as maintenance. If not working at week 12: verify product quality (third-party tested copper tripeptide content, not all 'GHK-Cu' products contain meaningful active ingredient). Consider whether your skin concern is dermatologic rather than cosmetic — see a dermatologist if so.

2. Phase 2 — +Systemic layer (Glow blend)

   8-12 weeks per cycle

   Add Glow blend SubQ for deeper collagen + healing work, layered on top of the Phase 1 topical maintenance. Glow is a pre-mixed community blend of BPC-157 + TB-500 + GHK-Cu. The systemic + topical combination is the editorial argument for layering — topical works locally on appearance markers; systemic supports the tissue substrate that determines how skin ages over years. No RCT validates this combined approach; the mechanism is coherent.

   • GHK-Cu1 mg · daily · evening

     Continue Phase 1 topical maintenance throughout the systemic cycle. The two layers work in parallel, not as alternatives.

   • Glow200 mcg · daily · evening

     200mcg of each blend component SubQ once daily during the cycle. Evening dosing aligns with sleep-state tissue repair. Cycle 8-12 weeks then pause for 4-8 weeks before re-cycling — community practice; no head-to-head evidence on optimal cycling cadence.

   What “working” looks like

   More noticeable skin-quality improvements than Phase 1 alone — increased firmness, faster post-blemish healing, possible scar fading over multi-cycle timescales. Hair density improvements (if that's a goal) often emerge here rather than in Phase 1. Energy + sleep often improve as BPC-157 secondary effects.

   Decision criteria

   After first 12-week cycle: pause for 4-8 weeks. If Phase 1+2 combined delivered meaningful improvement vs Phase 1 alone, schedule a second cycle. If no clear delta from Phase 1, discontinue Phase 2 — the cost + injection burden isn't justified. Continue Phase 1 topical indefinitely regardless.

3. Phase 3 — Optional pigmentation layer (melanotan)

   Loading 1-2 weeks + maintenance

   OPTIONAL — this is a separate consideration from the skin-appearance work above. Melanotan stimulates melanocytes via MC1R/MC4R signaling, producing darker pigmentation with reduced UV exposure relative to natural tanning. The use case is cosmetic; the medical analog (Scenesse for erythropoietic protoporphyria) is FDA-approved but for a rare disease unrelated to cosmetic tanning. Melanotan-1 (MT-1) is editorially preferable to Melanotan-2 (MT-2) for cosmetic use — MT-1 is more selective (MC1R) while MT-2 hits MC1R + MC4R + MC3R, producing additional side-effects (libido, hunger, mood changes). Loading phase produces faster pigmentation; maintenance keeps it.

   • GHK-Cu1 mg · daily · evening

     Continue topical foundation throughout — the pigmentation work is additive, not replacement.

   • Melanotan I500 mcg · daily · evening

     Loading phase: 0.5mg SubQ daily for 1-2 weeks until desired pigmentation. Then maintenance at 0.5mg 2-3x/week. Stop loading dose if any mole shows ANY change (size, color, asymmetry, raised edge) — see Caution #1.

   What “working” looks like

   Pigmentation emerges within 7-14 days of starting; deepens over 4-6 weeks. Most users achieve durable tan-like color without significant UV exposure. Side-effects (flushing, nausea, mild GI) most common in first 5-7 days; usually resolve.

   Decision criteria

   If any mole or skin lesion changes during Phase 3: STOP immediately and see a dermatologist. The melanocyte-stimulation mechanism is real; activating a pre-existing nevus is a real (if rare) concern. After loading: drop to maintenance 2-3x/week and continue indefinitely if pigmentation is the goal. If side-effects are bothersome (especially on MT-2 if you chose that): discontinue — the cosmetic benefit isn't worth the systemic effects.

Often combined with

• Recovery from Injury

  Phase 2 Glow blend overlaps with Recovery from Injury Phase 3 (which also uses GHK-Cu + BPC-157 + TB-500 individually). If running both protocols, do NOT double-dose the components — pick whichever protocol's Phase 2/3 came first and treat it as primary. The Skin protocol's topical Phase 1 stacks cleanly with Recovery's injectable phases.

• Longevity

  Phase 1 GHK-Cu topical is a clean addition to the Longevity protocol — different mechanism layer (local matrix remodeling vs systemic mTOR pulse), no interaction concerns. The two protocols address different aspects of aging (visible vs cellular) and complement well.